Arcutis ZORYVE Cream FDA Approved for Plaque Psoriasis in Children 2+

Arcutis Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the indication for ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis to children down to age 2. ZORYVE cream 0.3% is a once-daily, steroid-free topical therapy that is safe, effective, and well-tolerated for use anywhere on the body with no limitations on duration of use. This approval addresses a significant treatment gap for young children with plaque psoriasis and represents the seventh FDA approval for ZORYVE in four years.